Hepatitis B
Chronic Hepatitis B Treatment Guidelines
- Details
- Category: HBV Treatment
- Published on Tuesday, 04 February 2014 00:00
- Written by HIVandHepatitis.com
CHB Treatment Guideline Navigator
Mark Sulkowski from Johns Hopkins and Tram Tran from Cedars Sinai Medical Center help readers understand and make decisions using current guidelines for treatment of people with chronic hepatitis B. This continuing medical education (CME) activity is available for free to all, with credit available for physicians and nurses.
Monitoring Inactive Hepatitis B Is Cost-effective but Must Increase to Improve Survival
- Details
- Category: HBV Treatment
- Published on Tuesday, 28 January 2014 00:00
- Written by Wiley-Blackwell
Lifelong monitoring of people with inactive hepatitis B virus (HBV) infection may be cost-effective, according to a study in China published the December 19 advance online edition of Hepatology. Monitoring and treatment would have to be substantially expanded, however, to achieve significant reductions in liver cancer and hepatitis B-related mortality.
AASLD 2013: Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years
- Details
- Category: HBV Treatment
- Published on Wednesday, 04 December 2013 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to main viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC. Long-term kidney and bone-related side effects remained uncommon.
CDC Updates Guidance for Hepatitis B Vaccination of Health-care Providers
- Details
- Category: HBV Vaccines
- Published on Thursday, 16 January 2014 00:00
- Written by Liz Highleyman
The U.S. Centers for Disease Control and Prevention (CDC) has published updated guidance for evaluating and ensuring protection against hepatitis B virus (HBV) for health-care workers, as well as post-exposure prophylaxis recommendations for those without adequate vaccine protection.
AASLD 2013: Viral Hepatitis Epidemics in the U.S. and California
- Details
- Category: HBV Epidemiology & Mortality
- Published on Wednesday, 27 November 2013 00:00
- Written by Liz Highleyman
Deputy Assistant Secretary for Health Ronald Valdisseri described the hepatitis B and C epidemics in the U.S., the HCV cascade of care, and efforts to combat viral hepatitis at the AASLD Liver Meeting this month in Washington, DC. Public health officials in California also recently released a report on the hepatitis B and C epidemics in that state.
Adding Pegylated Interferon to Antivirals for Hepatitis B May Lead to HBsAg Loss
- Details
- Category: HBV Treatment
- Published on Monday, 23 December 2013 00:00
- Written by Liz Highleyman
Addition of pegylated interferon to nucleoside/nucleotide antivirals increases the likelihood of hepatitis B surface antigen (HBsAg) loss -- considered a cure -- in people with hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B, according to a report in December 2013 edition of Journal of Clinical Virology.
AASLD 2013: Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity
- Details
- Category: Experimental HBV Drugs
- Published on Thursday, 21 November 2013 00:00
- Written by Liz Highleyman
A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 64thAASLD Liver Meeting this month in Washington, DC.
Hepatitis B and C Reduce Survival by More than 20 Years
- Details
- Category: HBV Epidemiology & Mortality
- Published on Monday, 23 December 2013 00:00
- Written by Liz Highleyman
People with chronic hepatitis B or C lived about 2 decades less on average than those who did not have these infections, and chronic viral hepatitis was the 15th leading cause of death in the U.S. in 2010, CDC researchers reported in the January 1, 2014, issue of Clinical Infectious Diseases.
AASLD 2013: Hepatitis B Vaccine Protection Lasts at Least 30 Years
- Details
- Category: HBV Vaccines
- Published on Friday, 15 November 2013 00:00
- Written by Liz Highleyman
Hepatitis B vaccination provides long-term protection through 30 years for a majority of recipients, and more than 90% were protected with either initial immunization or a booster, according to a presentation at the 64th AASLD Liver Meeting last week in Washington, DC.
More Articles...
- AASLD 2013: Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure
- AASLD 2013: Hepatitis B Treatment with Entecavir or Tenofovir Lowers, But Does Not Eliminate, HCC Risk
- AASLD Liver Meeting Starts this Weekend in Washington, DC
- Coverage of the 2013 AASLD Liver Meeting
- IDWeek 2013: Entecavir and Tenofovir Both Work Well Against Hepatitis B in Clinical Practice
Web Design and Development by